CPT® Code 86051

The CPT® Code 86051 refers to the testing for Aquaporin-4 (AQP4) antibodies, which are significant markers for neuromyelitis optica (NMO), an autoimmune disorder characterized by inflammation and demyelination within the central nervous system (CNS). NMO primarily impacts the optic nerves and spinal cord, but it can also affect the brain, leading to a range of severe symptoms. These symptoms may include vision loss, limb weakness or paralysis, uncontrollable vomiting or hiccups, painful muscle spasms, and dysfunction of the bladder or bowel. In pediatric cases, the condition can manifest as seizures or even coma. The presence of AQP4 antibodies, also referred to as NMO-IgG, is crucial for distinguishing NMO from multiple sclerosis (MS), as these antibodies are typically found in individuals with NMO but not in those with classical MS. The testing process involves obtaining a venous blood sample, which is then analyzed using the enzyme-linked immunosorbent immunoassay (ELISA) method. This method is capable of detecting minute quantities of the antigen when it is bound to its specific antibody, utilizing a secondary enzyme-labeled antibody to indicate its presence through a chromogenic reaction that results in a visible color change or fluorescence. The results can be assessed qualitatively and semi-quantitatively through colorimetric readings. The AQP4 ELISA test serves as a vital tool for both initial diagnosis and ongoing monitoring of the disease, and it may be complemented by additional testing methods, such as a cell-based immunofluorescence assay (IFA), for further diagnostic clarity.